Evidence map›Paper›PMID 34436417›Full record

ArticleMetabolites2021

Untargeted Metabolomics Uncovers the Essential Lysine Transporter in

Joachim Kloehn, Matteo Lunghi, Emmanuel Varesio, David Dubois, Dominique Soldati-Favre

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Metabolomics: Going Deeper, Going Broader, Going Further.Methods in molecular biology (Clifton, N.J.) · 2023
    Review
  5. Article
  6. Review
  7. Dominique Soldati-Favre: BringingFrontiers in cellular and infection microbiology · 2022
    Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Joachim KloehnDepartment of Microbiology and Molecular Medicine, University of Geneva, CMU, Rue Michel-Servet 1, 1211 Geneva, Switzerland.ORCID 0000-0002-6366-8599
Matteo LunghiDepartment of Microbiology and Molecular Medicine, University of Geneva, CMU, Rue Michel-Servet 1, 1211 Geneva, Switzerland.
Emmanuel VaresioInstitute of Pharmaceutical Sciences of Western Switzerland, School of Pharmaceutical Sciences, Mass Spectrometry Core Facility (MZ 2.0), University of Geneva, 1211 Geneva, Switzerland.ORCID 0000-0002-6584-9756
David DuboisDepartment of Microbiology and Molecular Medicine, University of Geneva, CMU, Rue Michel-Servet 1, 1211 Geneva, Switzerland.
Dominique Soldati-FavreDepartment of Microbiology and Molecular Medicine, University of Geneva, CMU, Rue Michel-Servet 1, 1211 Geneva, Switzerland.ORCID 0000-0003-4156-2109
University of Geneva · CH

Funding

European 451 Union's Horizon 2020 research and innovation program 695596
6 · The paper itself

Abstract

Apicomplexan parasites are responsible for devastating diseases, including malaria, toxoplasmosis, and cryptosporidiosis. Current treatments are limited by emerging resistance to, as well as the high cost and toxicity of existing drugs. As obligate intracellular parasites, apicomplexans rely on the uptake of many essential metabolites from their host.

Indexed as

amino acidsApicomplexalysinemajor facilitator superfamilymetabolomicsobligate intracellular parasitesolute carrierstable isotope labelingToxoplasma gondiitransporteruntargeted metabolomics

Identifiers

PMID34436417
PMCPMC8399914
OpenAlexW3184783543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.